Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis

Purpose: Characterization of colorectal cancer transcriptome by high-throughput techniques has enabled the discovery of several differentially expressed genes involving previously unreported miRNA abnormalities. Here, we followed a systematic approach on a global scale to identify miRNAs as clinical outcome predictors and further validated them in the clinical and experimental setting. Experimental Design: Genome-wide miRNA sequencing data of 228 colorectal cancer patients from The Cancer Genome Atlas dataset were analyzed as a screening cohort to identify miRNAs significantly associated with survival according to stringent prespecified criteria. A panel of six miRNAs was further validated for their prognostic utility in a large independent validation cohort (n = 332). In situ hybridization and functional experiments in a panel of colorectal cancer cell lines and xenografts further clarified the role of clinical relevant miRNAs. Results: Six miRNAs (miR-92b-3p, miR-188-3p, miR-221-5p, miR-331-3p, miR-425-3p, and miR-497-5p) were identified as strong predictors of survival in the screening cohort. High miR-188-3p expression proves to be an independent prognostic factor [screening cohort: HR = 4.137; 95% confidence interval (CI), 1.568–10.917; P = 0.004; validation cohort: HR = 1.538; 95% CI, 1.107–2.137; P = 0.010, respectively]. Forced miR-188-3p expression increased migratory behavior of colorectal cancer cells in vitro and metastases formation in vivo (P < 0.05). The promigratory role of miR-188-3p is mediated by direct interaction with MLLT4, a novel identified player involved in colorectal cancer cell migration. Conclusions: miR-188-3p is a novel independent prognostic factor in colorectal cancer patients, which can be partly explained by its effect on MLLT4 expression and migration of cancer cells. Clin Cancer Res; 23(5); 1323–33. ©2016 AACR.

[1]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[2]  D. Birnbaum,et al.  Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth , 2011, Oncogene.

[3]  R. Spizzo,et al.  Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. , 2012, Gastroenterology.

[4]  Huawei Zeng,et al.  Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. , 2013, Gastroenterology.

[5]  Rebecca L. Siegel Mph,et al.  Colorectal cancer statistics, 2014 , 2014 .

[6]  R. Spizzo,et al.  The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis , 2015, Gut.

[7]  Yanlei Ma,et al.  miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer , 2011, Gut.

[8]  Y. Toiyama,et al.  MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis , 2012, Gut.

[9]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[10]  Yuzhuo Wang,et al.  miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression , 2015, Oncotarget.

[11]  G. Calin,et al.  MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients , 2015, British Journal of Cancer.

[12]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[13]  H. Brenner,et al.  MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[14]  J. Goeman,et al.  MicroRNA Classifier and Nomogram for Metastasis Prediction in Colon Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[15]  A. Krasinskas,et al.  Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. , 2011, Seminars in oncology.

[16]  H. Lenz,et al.  Predictive and prognostic markers in the treatment of metastatic colorectal cancer (mCRC): personalized medicine at work. , 2015, Hematology/oncology clinics of North America.

[17]  Kieran Sheahan,et al.  Controversies in the pathological assessment of colorectal cancer. , 2014, World journal of gastroenterology.

[18]  A. Bardelli,et al.  Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.

[19]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[20]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Stefano Volinia,et al.  MicroRNA Profiles Discriminate among Colon Cancer Metastasis , 2014, PloS one.

[22]  Wei Wei,et al.  Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression , 2015, Nature Communications.

[23]  Jian Lu,et al.  Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. , 2013, The Lancet. Oncology.

[24]  S. Gill,et al.  Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes. , 2014, Cancer treatment reviews.

[25]  W. Xie,et al.  MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes , 2014, Cell Communication and Signaling.

[26]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[27]  A. Jemal,et al.  Colorectal cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[28]  Philip Quirke,et al.  The future of the TNM staging system in colorectal cancer: time for a debate? , 2007, The Lancet. Oncology.

[29]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Sabine Tejpar,et al.  Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[31]  P. Ubezio,et al.  A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Tseng,et al.  MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer , 2012, Oncogene.

[33]  M. Asslaber,et al.  A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients , 2014, Clinical Cancer Research.

[34]  J. Foekens,et al.  CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer , 2013, Genome research.

[35]  M. Ferracin,et al.  MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab , 2015, Oncotarget.